Genmab reports Phase 3 trial of Rina‑S cuts progression risk by 71% in platinum‑resistant ovarian cancer

Genmab announced that its investigational ADC Rina‑S met the primary endpoint of progression‑free survival and the key secondary endpoint of overall survival in the global Phase 3 RAINFOL‑02 trial for platinum‑resistant ovarian cancer. In the intent‑to‑treat population of 584 patients, the drug reduced the risk of disease progression or death by 71% (hazard ratio 0.29) and lowered overall‑survival risk by 57% (hazard ratio 0.43). The company said it will engage regulators worldwide and present the data at a future medical meeting.

The company expects regulatory discussions to follow, which could lead to approval and add a new revenue stream beyond its existing DARZALEX royalties (the company says). The trial’s strong efficacy may also boost the stock, as shares rose about 9% after the announcement.

  • 1The intent‑to‑treat (ITT) population included 584 randomized patients.
  • 2In the ITT population, Rina‑S reduced the risk of disease progression or death by 71% (hazard ratio 0.29; 95% CI 0.23‑0.37; p<0.0001).
  • 3In the primary analysis set (PAS) of 492 patients, the risk reduction was 67% (hazard ratio 0.33; 95% CI 0.26‑0.42; p<0.0001).
  • 4Overall‑survival risk was reduced by 57% in the ITT population (hazard ratio 0.43; 95% CI 0.31‑0.59; p<0.0001).
  • 5Genmab’s shares rose roughly 9% after the announcement.
  • 6Genmab will host an investor update on October 28 at 5:00 p.m. CET/12:00 p.m. EDT.

Sources